HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: prasterone significantly reduces lupus flares

(Date:7/31/2014)... Ohio (PRWEB) July 31, 2014 In ... that the pharmaceutical giant, Johnson & Johnson, is withdrawing ... it can spread undetected cancer. This important story ... (7/30), USA Today (7/31), the AP (7/30), the Pittsburgh ... morcellator tool is used during uterine procedures to, “slice ...
(Date:7/31/2014)... , Rest assured, there is a happy ending, ... shows that many college students are stressed out and ... there are simple ways for students to relieve stress ... of UC,s Health Promotion and Education Program. The trouble ... a whole array of different stress-management techniques college students ...
(Date:7/31/2014)... July 31, 2014 The Never Give Up ... supporters from11:00am-11:00pm on August 7th. Simply bring your ticket ... great food and beverages with friends and family. ... His amazing passion and contagious optimism continues to impact ... positive attitude in effort to pursue a happy life was ...
(Date:7/31/2014)... The “Nucleic Acid Isolation and ... Magnetic bead based), Consumables & Instruments, by Application ... End users - Global Forecasts to 2018” provides ... challenges, opportunities, current market trends, and strategies impacting ... along with the estimates and forecasts of the ...
(Date:7/31/2014)... 2014 Ticket Down is a reputable ... in Santa Clara, California. Fans in the United States of ... the best club and national teams in the world. Coming off ... has become the best time to be a fan of soccer ... being held on American soil this year, as well as international ...
Breaking Medicine News(10 mins):Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 2Health News:Have You Had a Hysterectomy or Removal of Uterine Fibroids? Morcellator Device Withdrawn From Market Due To Cancer Risk 3Health News:Simple tips to fend off freak-outs 2Health News:Simple tips to fend off freak-outs 3Health News:Don't Forget To Mention Never Give Up 26 Foundation 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Nucleic Acid Isolation Market Worth $3,106.28 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 2Health News:Mexico vs. Chile Tickets Levi’s Stadium: Ticket Down Slashes Ticket Prices for Chile vs. Mexico at Levi’s Stadium in Santa Clara, California on September 6th 3
(Date:7/31/2014)...  Today, Levi Ray & Shoup, ... PageCenterX ® content management solution. PageCenterX/Satellite ... downtime reporting capabilities to healthcare organizations during planned ... product for general availability, effective today. ... for a variety of reasons," said John ...
(Date:7/31/2014)... , July 31, 2014 Orexigen® Therapeutics, ... results for the second quarter 2014, on Thursday, August ... followed by a live webcast and conference call at ... Orexigen management will host the call and webcast ... live call may be accessed by calling (800) 708-4540 ...
(Date:7/31/2014)... SCOTTSDALE, Ariz. , July 31 2014  Northsight ... Bluher has been named Chairman and CEO of ... governance, risk management, legal matters, business development and investment ... in the securities industry.  Before his career on Wall ... Enforcement Division of the U.S, Securities and Exchange Commission ...
Breaking Medicine Technology:LRS Announces Downtime Reporting Solution for Healthcare 2Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Northsight Capital, Inc. Names Wall Street Veteran John Bluher, Former EVP And General Counsel Of Knight Trading Group, Chairman And CEO. 2
Cached News: